| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 108 |
| 1 | DEXAMETHASONE | 77 |
| 2 | DEXAMETHASONE 1.5 MG | 77 |
| 3 | CABOZANTINIB | 68 |
| 4 | TRASTUZUMAB | 67 |
| 5 | CAPECITABINE | 63 |
| 6 | EVEROLIMUS | 63 |
| 7 | ACETAMINOPHEN | 60 |
| 8 | ONDANSETRON HYDROCHLORIDE | 60 |
| 9 | OCTREOTIDE ACETATE | 59 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIROGACESTAT | 19 | 0.0206 |
| 1 | PEXIDARTINIB HYDROCHLORIDE | 7 | 0.0098 |
| 2 | NERATINIB | 18 | 0.0078 |
| 3 | SELUMETINIB | 11 | 0.0065 |
| 4 | RIPRETINIB | 26 | 0.0050 |
| 5 | TAZEMETOSTAT | 6 | 0.0037 |
| 6 | TALIMOGENE LAHERPAREPVEC | 5 | 0.0031 |
| 7 | APREPITANT | 19 | 0.0025 |
| 8 | LANREOTIDE ACETATE | 20 | 0.0025 |
| 9 | ADO-TRASTUZUMAB EMTANSINE | 20 | 0.0024 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 276 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 180 |
| 2 | Corticosteroid [EPC] | 138 |
| 3 | Opioid Agonist [EPC] | 117 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 111 |
| 5 | Microtubule Inhibitor [EPC] | 87 |
| 6 | Benzodiazepine [EPC] | 79 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 75 |
| 8 | Platinum-based Drug [EPC] | 73 |
| 9 | HER2/neu Receptor Antagonist [EPC] | 70 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Gamma Secretase Inhibitor [EPC] | 19 | 0.0206 |
| 1 | Farnesyltransferase Inhibitor [EPC] | 1 | 0.0128 |
| 2 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 3 | 0.0050 |
| 3 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 19 | 0.0022 |
| 4 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 2 | 0.0018 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 180 | 0.0018 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 7 | 0.0017 |
| 7 | Guanylate Cyclase-C Agonist [EPC] | 3 | 0.0014 |
| 8 | Provitamin D2 Compound [EPC] | 35 | 0.0012 |
| 9 | CTLA-4-directed Blocking Antibody [EPC] | 51 | 0.0011 |